Focus: ADARx Pharmaceuticals is an RNA therapeutics company focused on neurology and gene therapy based in San Diego. The company operates across early-to-late stage development with a diversified pipeline targeting rare and serious diseases.
Profile data last refreshed 16m ago · AI intelligence enriched 3w ago
Cooling — net -6 jobs in 30d
1 added, 7 removed. Slower than typical.
ADARx is a promising RNA therapeutics player with a late-stage asset in hand, but career risk depends heavily on undisclosed funding adequacy and operational scale.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for ADARx Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from ADARx Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles